Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$39.05
-2.6%
$34.92
$21.62
$40.40
$7.41B1.12.47 million shs2.23 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$14.25
-0.3%
$11.16
$8.02
$18.80
$7.08B1.675.16 million shs4.42 million shs
Schrödinger, Inc. stock logo
SDGR
Schrödinger
$26.69
+2.1%
$23.48
$16.60
$28.47
$1.96B1.63881,694 shs1.46 million shs
Verona Pharma plc stock logo
VRNA
Verona Pharma
$90.05
+3.8%
$69.56
$13.60
$92.98
$7.30B0.211.33 million shs2.83 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-2.59%+2.71%+9.45%+20.86%+42.10%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-0.22%+5.88%+11.20%+38.16%-22.34%
Schrödinger, Inc. stock logo
SDGR
Schrödinger
+2.14%+12.47%+10.43%+21.71%+27.10%
Verona Pharma plc stock logo
VRNA
Verona Pharma
+3.77%+7.23%+33.35%+37.78%+573.52%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
4.5446 of 5 stars
4.51.00.03.92.63.30.6
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.1316 of 5 stars
1.21.00.00.31.43.30.0
Schrödinger, Inc. stock logo
SDGR
Schrödinger
1.5661 of 5 stars
2.51.00.00.03.12.50.6
Verona Pharma plc stock logo
VRNA
Verona Pharma
1.869 of 5 stars
2.61.00.00.04.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.92
Moderate Buy$57.3646.90% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.43
Hold$15.176.43% Upside
Schrödinger, Inc. stock logo
SDGR
Schrödinger
3.00
Buy$32.8022.89% Upside
Verona Pharma plc stock logo
VRNA
Verona Pharma
3.10
Buy$87.44-2.89% Downside

Current Analyst Ratings Breakdown

Latest SDGR, BBIO, ELAN, and VRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $100.00
6/11/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$95.00 ➝ $110.00
6/9/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$53.00 ➝ $56.00
6/2/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$85.00 ➝ $90.00
5/19/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
5/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
4/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$46.00 ➝ $63.00
4/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $55.00
4/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$65.00 ➝ $72.00
4/30/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$93.00 ➝ $107.00
4/30/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$75.00 ➝ $85.00
(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$127.42M58.19N/AN/A($7.71) per share-5.06
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.43B1.60$2.94 per share4.84$12.63 per share1.13
Schrödinger, Inc. stock logo
SDGR
Schrödinger
$230.49M8.50$0.71 per share37.42$7.60 per share3.51
Verona Pharma plc stock logo
VRNA
Verona Pharma
$118.54M61.60N/AN/A$3.10 per share29.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$535.76M-$3.53N/AN/AN/A-241.44%N/A-75.69%7/30/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$1.23B$0.7435.6316.012.504.60%6.78%3.03%8/6/2025 (Estimated)
Schrödinger, Inc. stock logo
SDGR
Schrödinger
$40.72M-$2.63N/AN/AN/A-91.84%-35.77%-24.51%7/30/2025 (Estimated)
Verona Pharma plc stock logo
VRNA
Verona Pharma
-$54.37M-$2.00N/A3,001.67N/AN/A-79.54%-43.49%8/14/2025 (Estimated)

Latest SDGR, BBIO, ELAN, and VRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/7/2025Q1 2025
Schrödinger, Inc. stock logo
SDGR
Schrödinger
-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million
4/29/2025Q1 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 million
4/29/2025Q1 2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Schrödinger, Inc. stock logo
SDGR
Schrödinger
N/AN/AN/AN/AN/A
Verona Pharma plc stock logo
VRNA
Verona Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
4.67
4.67
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.66
2.55
1.31
Schrödinger, Inc. stock logo
SDGR
Schrödinger
N/A
4.11
4.11
Verona Pharma plc stock logo
VRNA
Verona Pharma
0.93
13.03
12.88

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Schrödinger, Inc. stock logo
SDGR
Schrödinger
79.05%
Verona Pharma plc stock logo
VRNA
Verona Pharma
85.88%

Insider Ownership

CompanyInsider Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
18.20%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Schrödinger, Inc. stock logo
SDGR
Schrödinger
8.60%
Verona Pharma plc stock logo
VRNA
Verona Pharma
4.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400189.88 million143.29 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,800496.65 million491.54 millionOptionable
Schrödinger, Inc. stock logo
SDGR
Schrödinger
79073.38 million66.59 millionOptionable
Verona Pharma plc stock logo
VRNA
Verona Pharma
3081.08 million76.10 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$39.05 -1.04 (-2.59%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$39.05 0.00 (0.00%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$14.25 -0.05 (-0.34%)
Closing price 06/11/2025 03:59 PM Eastern
Extended Trading
$14.27 +0.02 (+0.13%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Schrödinger stock logo

Schrödinger NASDAQ:SDGR

$26.69 +0.56 (+2.14%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$26.76 +0.07 (+0.28%)
As of 07:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Verona Pharma stock logo

Verona Pharma NASDAQ:VRNA

$90.05 +3.27 (+3.77%)
Closing price 06/11/2025 04:00 PM Eastern
Extended Trading
$91.16 +1.12 (+1.24%)
As of 07:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.